# Platinum-Based Chemotherapy Nephrotoxicity: Deep Dive Review

**Written for:** Experienced nephrologist audience from onco-nephrology perspective **Board-Review Depth:** Yes \| **Practical Management:** Yes

------------------------------------------------------------------------

## OVERVIEW & CLINICAL RELEVANCE

Platinum-based agents remain cornerstone chemotherapy for multiple solid tumors (testicular, ovarian, lung, head/neck, bladder). Despite decades of use, nephrotoxicity remains the dose-limiting or dose-modifying factor for patients with pre-existing renal impairment or cumulative exposure. The nephrologist is increasingly consulted for:

- Baseline renal function optimization before platinum exposure
- AKI management during/after platinum chemotherapy
- Long-term renal outcomes in platinum-treated cancer survivors
- Dose adjustment decisions in CKD patients
- Management of platinum-induced electrolyte wasting syndromes

------------------------------------------------------------------------

## CISPLATIN: THE MOST NEPHROTOXIC PLATINUM AGENT

### Epidemiology & Incidence

**Clinical Pearl:** Cisplatin is the **\#1 cause of chemotherapy-induced acute kidney injury**, accounting for ~20–30% AKI incidence at standard doses (70–100 mg/m²) and up to **70–80% with cumulative high-dose exposure** (\>500 mg/m²).

- Cumulative dose-dependent: Risk escalates significantly above 300 mg/m² lifetime
- Acute AKI typically reversible (Cr rise within days 3–7, recovery over 2–4 weeks)
- Chronic kidney disease: 10–30% of cisplatin-treated patients develop lasting eGFR decline (stage 3–4 CKD)
- Hypomagnesemia: 40–100% depending on dose and follow-up duration

### Mechanism of Proximal Tubule Injury \[1,2,3\]

**Key Point:** Cisplatin nephrotoxicity is fundamentally a **proximal tubule disease**, not glomerular.

#### Cellular Transport & Uptake

- Filtered cisplatin is reabsorbed across proximal tubule epithelium via:
  - **OCT2 (SLC22A2)**: organic cation transporter 2 — *primary apical uptake mechanism*
  - **CTR1**: copper transporter 1 — facilitates Pt uptake
  - **MATE1**: multidrug extrusion transporter — basolateral efflux (limited efficiency)
- High intracellular Pt concentrations (5–10× plasma) lead to massive local toxicity
- Proximal tubule most vulnerable because it actively reabsorbs and concentrates filtered drugs

#### DNA Damage & Apoptosis Cascade

1.  **Intracellular Pt binding to DNA** → adduct formation
2.  **p53 activation** → cell cycle arrest, apoptosis initiation \[2\]
3.  **Mitochondrial dysfunction:**
    - Inhibition of respiratory chain complexes I–IV
    - Decreased ATP production → impaired tubular function
    - Loss of mitochondrial membrane potential
    - Reduced mitochondrial calcium uptake capacity \[2\]
4.  **Reactive oxygen species (ROS) accumulation:**
    - Mitochondrial superoxide production (Complex I/III)
    - Glutathione (GSH) depletion → oxidative stress
    - Lipid peroxidation, protein nitrosylation
5.  **Caspase activation** → apoptosis and tubular necrosis

#### Additional Mechanisms

- **Inflammatory response:** NF-κB activation, IL-6/TNF-α release
- **Altered transporter expression:** Down-regulation of Na-K-ATPase, aquaporins (impaired concentrating ability)
- **Tubular cast formation:** Tamm-Horsfall protein aggregation (can contribute to AKI in some cases)
- **Renal hemodynamic changes:** Transient afferent arteriole vasoconstriction

### Clinical Presentation of Cisplatin AKI

| Timing | Presentation | Key Features |
|----|----|----|
| **Days 3–7 post-dose** | Acute Kidney Injury | Serum Cr ↑30–50%; Non-oliguric; Peak Cr at day 5–7 |
| **With cumulative exposure** | Chronic CKD | Baseline Cr creep; Persistent eGFR decline; Proteinuria (usually non-nephrotic) |
| **Concurrent electrolyte** | Hypomagnesemia, hypokalemia | **BOARD POINT:** Hypomagnesemia present in 40–100%; Often unrecognized; Can persist years |

### Complicating Renal Lesions

#### Fanconi Syndrome (10–20% incidence)

- Proximal tubule dysfunction → wasting of:
  - Phosphate, glucose, amino acids, bicarbonate
  - Can occur acutely or develop insidiously with cumulative dose
- Clinical consequence: Hypophosphatemia, renal tubular acidosis (RTA type 2), growth retardation in pediatric survivors
- Usually improves over months post-therapy but can be permanent

#### Chronic Tubulointerstitial Nephritis

- Pathology: Tubular atrophy, interstitial fibrosis, chronic inflammation
- Progressive eGFR decline in subset of patients
- May reflect cumulative damage threshold (~300 mg/m²)
- Biopsy finding in long-term follow-up studies

#### Hypomagnesemia (CRITICAL)

**Board Point:** Cisplatin-induced hypomagnesemia is **extremely common, often missed, and clinically consequential.**

- **Mechanism:** Direct proximal tubule injury → impaired Mg reabsorption (thick ascending limb also affected)
- **Incidence:** 50–100% depending on dose and follow-up
- **Onset:** Days 3–5, can persist or worsen for months
- **Complications:**
  - Hypokalemia (refractory without Mg repletion)
  - Hyponatremia (SIADH-like pattern)
  - Cardiac arrhythmias
  - Neurotoxicity exacerbation
- **Management:** IV Mg replacement (10–20 mEq per dose, repeat based on levels); often needed weekly × 4–6 weeks or longer

------------------------------------------------------------------------

## CARBOPLATIN: REDUCED NEPHROTOXICITY PROFILE

### Epidemiology & Renal Tolerability

- **Incidence of AKI:** \<5% (vs. 20–30% for cisplatin)
- **Incidence of hypomagnesemia:** \<10%
- **Reason:** Carboplatin is less nephrotoxic due to different chemical structure and reduced proximal tubule uptake

### Calvert Formula & Dose Adjustment in CKD

**Key Point:** Carboplatin dosing is **AUC-based** (area under curve), NOT flat mg/m². This is critical for dose adjustment in renal impairment.

**Calvert Formula:**

    Dose (mg) = AUC × (GFR + 25)
    GFR = (140 - age) × weight(kg) / (72 × Cr[mg/dL])
          × 0.85 if female

**Clinical Pearl:** - Standard AUC = 6.0 mg·min/mL (or target specified by protocol) - In CKD (eGFR 30–60): Calculate actual GFR; usually minor dose reduction - In CKD (eGFR \<30): Significant dose reduction; often discontinue if eGFR \<20 (hematologic toxicity becomes dose-limiting) - Renal function should be re-assessed before each cycle

### Renal Side Effects

- **Thrombocytopenia:** Dose-limiting (NOT nephrotoxicity)
- **Minimal direct renal toxicity:** No hypomagnesemia, rare AKI
- **Electrolyte abnormalities:** Uncommon
- **Acceptable in moderate CKD:** But watch for accumulation if creatinine clearance \<50

------------------------------------------------------------------------

## OXALIPLATIN: RARE NEPHROTOXICITY, DIFFERENT TOXICITY PROFILE

### Renal Safety Profile

- **Nephrotoxicity:** Extremely rare (\<1% incidence of AKI)
- **Hypomagnesemia:** Uncommon
- **Main dose-limiting toxicity:** Acute neurotoxicity (reversible) and cumulative peripheral neuropathy (CIPN)

### Occasional Renal Presentations

#### Thrombotic Microangiopathy (TMA)

- Rare but reported \[case reports\]
- Mechanism: Endothelial injury (different from VEGF-inhibitor TMA)
- Management: Hold oxaliplatin; supportive care; usually reversible

#### Crystal Nephropathy (Oxalate Crystals)

- Massive oxalate precipitation in tubules
- Extremely rare; reported in setting of high-dose, rapid infusion with dehydration
- Prevention: Adequate IV hydration

------------------------------------------------------------------------

## PREVENTION OF PLATINUM NEPHROTOXICITY

### Aggressive Hydration: The Gold Standard

**Board Point:** Pre- and post-treatment hydration is the **single most effective preventive measure** for cisplatin nephrotoxicity.

| Strategy | Details | Evidence |
|----|----|----|
| **Pre-hydration** | 1–2 L normal saline IV over 1–2 hours before cisplatin | Reduces AKI by 50% |
| **Post-hydration** | 1–2 L normal saline IV over 6–8 hours after cisplatin | Ongoing Cr prevention |
| **Total daily target** | 2–3 L IV (goal urine output 100–200 mL/hr during/after treatment) | Maintains renal perfusion, dilutes intratubular Pt concentration |
| **Monitoring** | Assess volume status; avoid overload in heart failure/renal patients | Daily weights, orthostatics |

**Clinical Pearl:** Hydration is the reason **carboplatin is “safer”** — dose reduction already accounts for renal impairment. Cisplatin in CKD requires aggressive hydration to mitigate risk.

### Mannitol or Forced Diuresis (Controversial)

**Old dogma:** Mannitol + furosemide (“forced diuresis”) offered additional protection.

**Current evidence:** - No clear superiority over hydration alone \[3\] - Diuretics may impair Mg reabsorption → *worsens* hypomagnesemia - Can worsen electrolyte wasting (Na, K, Mg) - **Recommendation:** Reserve for volume overload only; not routine

### Amifostine: Selective Protector

**Mechanism:** Free radical scavenger; protects normal tissue while preserving tumor Pt uptake.

**Evidence:** - Reduces AKI incidence by ~30–40% in cisplatin-treated patients \[published trials\] - Reduces hypomagnesemia by ~20–30% - Cost: ~\$500–\$1000 per dose - Side effects: Hypotension (transient), nausea, allergy reactions

**Current use:** Reserved for **salvage cisplatin** in patients with baseline CKD or prior high cumulative dose. Not routine.

### Magnesium Supplementation (CRITICAL PREVENTION)

**Key Point:** Prophylactic Mg replacement before/during cisplatin can **reduce hypomagnesemia incidence** and improve patient tolerability.

| Approach | Details |
|----|----|
| **Baseline Mg check** | Get serum Mg before each cycle; normal \>2.0 mg/dL |
| **Prophylactic repletion** | IV Mg (10 mEq) 24 hours post-cisplatin, repeat weekly ×4–6 weeks if \<2.0 mg/dL |
| **Threshold for treatment** | Mg \<2.0: symptomatic (arrhythmia, tetany), start IV repletion |
| **Oral supplementation** | Marginal efficacy due to absorption limitations; GI side effects common |

**Recent evidence (2025):** Magnesium may **limit platinum accumulation in tubular cells** by modulating OCT2 and other renal transporters, providing mechanistic rationale for prevention \[recent review\].

------------------------------------------------------------------------

## MONITORING DURING PLATINUM THERAPY

### Baseline & Pre-Treatment Assessment

- **Serum Cr, eGFR:** Establish baseline; reassess within 72 hours post-treatment
- **Urine electrolytes & output:** Baseline for comparison
- **Magnesium, potassium, phosphate, calcium:** Comprehensive metabolic panel
- **Audiometry:** Cisplatin causes hearing loss (high-frequency); baseline audiology recommended for high-dose regimens
- **24-hour urine protein:** Baseline; repeat monthly if proteinuria develops

### Monitoring Schedule During & After Treatment

| Timepoint | Tests | Rationale |
|----|----|----|
| **Day 0 (before)** | Cr, eGFR, BMP | Baseline; assess hydration needs |
| **Day 3–5** | Cr, BMP (especially Mg, K, PO4) | Peak AKI window; hypomagnesemia detection |
| **Day 7** | Cr, BMP | Recovery assessment |
| **Weekly ×4** | Cr, Mg, K, PO4 | Ongoing electrolyte wasting |
| **Before next cycle** | Cr, eGFR, BMP | Determine dose/continue eligibility |
| **Audiometry** | At baseline, after cumulative dose \>300 mg/m² | Ototoxicity assessment |

### Red Flags Requiring Intervention

- Cr rise \>30% from baseline → discuss with oncology; consider dose reduction, hold cycle
- Serum Mg \<1.5 mg/dL → IV repletion; assess for symptomatic hypomagnesemia
- Urine output \<500 mL/day despite hydration → assess volume status; possible AKI
- Proteinuria \>2 g/day → evaluate with UA/urine electrophoresis; rule out concomitant glomerular disease

------------------------------------------------------------------------

## DOSING CISPLATIN IN CHRONIC KIDNEY DISEASE

### Decision Tree: When to Switch or Adjust

    eGFR Assessment:
    ├─ eGFR ≥45: Cisplatin standard dose feasible
    │  └─ Require aggressive hydration + baseline Mg repletion
    ├─ eGFR 30–44: Reduced cisplatin dose (50–75%) OR switch to carboplatin
    │  └─ Discuss with oncology; carboplatin preferred if chemotherapy non-curative
    ├─ eGFR <30: Carboplatin preferred
    │  └─ Cisplatin generally contraindicated (cumulative toxicity risk)
    └─ On dialysis: Use carboplatin (easier dosing, less ototoxicity)
       └─ Coordinate with dialysis schedule; consider HD timing relative to chemo

### Practical Dosing Adjustments

| CKD Stage | eGFR (mL/min) | Cisplatin Recommendation | Carboplatin Adjustment |
|----|----|----|----|
| 1–2 | ≥45 | Standard dose | Standard AUC |
| 3a | 45–59 | Standard dose + aggressive hydration | Standard AUC |
| 3b | 30–44 | 50% dose reduction OR switch to carboplatin | Reduce AUC by 20–30% |
| 4 | 15–29 | Carboplatin preferred | Calculate by Calvert; AUC usually 3–4 |
| 5 | \<15 or on dialysis | Avoid cisplatin | Carboplatin (HD schedule coordination) |

**Board Point:** eGFR \<30 + cisplatin = **high-risk combination**; cisplatin-induced AKI can precipitate need for dialysis in this population.

------------------------------------------------------------------------

## LONG-TERM RENAL OUTCOMES IN PLATINUM-TREATED SURVIVORS

### Persistent eGFR Decline Post-Therapy

**Key Statistic:** 10–30% of cisplatin-treated patients have **lasting ≥10 mL/min decline** in GFR compared to baseline, persisting years to decades post-therapy.

- Mean decline: 10–15 mL/min/1.73m² (when cumulative dose \>300 mg/m²)
- Risk factors for chronic sequelae:
  - Cumulative dose \>400 mg/m²
  - Baseline CKD or risk factors (hypertension, diabetes)
  - Older age at treatment
  - Concomitant nephrotoxic agents (amphotericin B, NSAIDs)

### Proteinuria in Survivors

- **Incidence:** 15–25% have persistent low-grade proteinuria (\<1 g/day)
- **Mechanism:** Tubular dysfunction (Fanconi syndrome component)
- **Significance:** Not nephrotic; usually benign; correlates with degree of proximal tubule injury
- **Management:** Monitor annually; RAAS inhibition if HTN

### Ototoxicity & Renal Outcomes (Shared Mechanism)

**Clinical Pearl:** Cisplatin-induced hearing loss and nephrotoxicity **share similar mechanisms** (oxidative stress, mitochondrial dysfunction). Patients with severe ototoxicity often have worse renal outcomes.

### Long-Term Follow-Up Recommendations

- **Annual Cr/eGFR:** For life (or until stable ×3 years)
- **Baseline CKD risk stratification:** HTN control, diabetes management
- **Avoid nephrotoxic agents:** NSAIDs, ACE-I/ARB if eGFR \<30 (unless specific indication)
- **Audiology follow-up:** If significant hearing loss, may indicate need for closer renal monitoring

------------------------------------------------------------------------

## CLINICAL MANAGEMENT ALGORITHMS

### Algorithm 1: Pre-Chemotherapy Renal Assessment

    Patient with planned platinum chemotherapy
        ↓
    Measure Cr, calculate eGFR (KDIGO 2021 formula)
        ↓
    eGFR ≥45? → Yes → Cisplatin feasible → Plan aggressive hydration + Mg repletion
                 No ↓
    Discuss with oncology: curative vs. palliative intent?
        ├─ Curative → Switch to carboplatin OR reduce cisplatin + enhanced hydration
        └─ Palliative → Consider non-platinum agents; carboplatin if Pt essential
        ↓
    Assess volume status, CHF, cirrhosis
        ├─ Yes → Careful fluid management; consider amifostine
        └─ No → Standard hydration protocol
        ↓
    Check baseline Mg, K, PO4; start Mg repletion if low-normal
        ↓
    Plan post-treatment monitoring (see table above)

### Algorithm 2: Management of Platinum-Induced AKI

    Post-platinum AKI (Cr rise ≥30% from baseline within 3–7 days)
        ↓
    Assess volume status & urine output
        ├─ Hypovolemic → Fluid resuscitation; target UOP 100–200 mL/hr
        ├─ Euvolemic → Maintenance hydration
        └─ Hypervolemic → Diuretics; hold further hydration; assess for CHF/cirrhosis
        ↓
    Check metabolic panel urgently: K↑?, Mg↓?, PO4↑?
        ├─ Hyperkalemia → Treat per AKI protocol (insulin, bicarb, kayexalate)
        ├─ Hypomagnesemia → IV Mg 10–20 mEq q8h; recheck q4h if severe
        └─ Hyperphosphatemia → Assess for TLS; phosphate binders if needed
        ↓
    Determine Cr trajectory
        ├─ Improving (Cr declining) → Continue hydration; step down as Cr stabilizes
        ├─ Stable → Maintenance hydration; monitor closely
        └─ Worsening (Cr still rising) → ↓ UOP after day 5? Consider dialysis consult
        ↓
    Assess need for continued chemotherapy
        ├─ Reversible AKI + curative regimen → Resume next cycle (eGFR permitting)
        └─ Severe/persistent AKI → Switch to carboplatin or non-Pt agents
        ↓
    Long-term: Plan electrolyte repletion regimen; monthly Cr checks ×3 months

------------------------------------------------------------------------

## TOXICITY GRADING & WHEN TO HOLD/MODIFY

### CTCAE v5.0 Grading for Renal Dysfunction

| Grade | Cr Change | Management |
|----|----|----|
| **1** | 1.5× baseline | Continue treatment; monitor closely |
| **2** | 1.5–3× baseline | Discuss with oncology; consider dose reduction or hold 1 cycle |
| **3** | \>3× baseline | Hold treatment; fluid resuscitation; nephrology consult |
| **4** | Acute kidney injury requiring intervention | Hold; ICU-level care; possible dialysis; switch to non-Pt agents if recovery slow |

### Threshold for Holding Cisplatin Doses

- **Absolute:** eGFR \<20 (carboplatin preferred)
- **Relative:** eGFR 20–30 + AKI in prior cycle
- **Physician discretion:** eGFR 30–45 + cumulative dose \>300 mg/m² (may switch to carboplatin or reduce intensity)

------------------------------------------------------------------------

## RELATED RESOURCES & FURTHER READING

- vegf tki nephrotoxicity review — Comparison of nephrotoxicity profiles; synergistic risk with Pt + VEGF inhibitors
- hematologic malignancies kidney review — Renal complications in hematologic cancers (some treated with Pt agents)
- electrolyte acid base review — Deep dive on platinum-induced Mg/K/PO4 wasting
- Acute Kidney Injury Hub — General AKI management principles applicable to chemotherapy-induced AKI
- Electrolyte Acid Base Hub — Hypomagnesemia and refractory hypokalemia management

------------------------------------------------------------------------

## CITED REFERENCES

\[1\] **Mechanisms of Cisplatin-Induced Acute Kidney Injury** — PMC 8036620; comprehensive review of proximal tubule uptake, DNA damage, mitochondrial dysfunction, ROS, and apoptosis pathways. PMID: 33805488

\[2\] **Molecular Mechanisms of Cisplatin-Induced Nephrotoxicity: A Balance on the Knife Edge** — PMC 6417243; discusses p53 signaling, Nrf2 oxidative stress response, mTOR, AMPK pathways. PMID: 30866950

\[3\] **Cumulative DNA Damage by Repeated Low-Dose Cisplatin** — Nature Scientific Reports 11, 2021; demonstrates transition of acute to chronic kidney injury with repeated exposure. PMID: 34686727

\[4\] **Mechanism of Cisplatin Proximal Tubule Toxicity Revealed by Integrating Transcriptomics, Proteomics, Metabolomics** — PubMed 25450742; multi-omics approach to understanding cellular injury mechanisms. PMID: 25450742

\[5\] **Caught in the Crossfire: Cancer, Cisplatin Therapy, and Kidney Injury** — American Journal of Physiology-Renal Physiology, 2023; recent comprehensive review. PMID: 36892907

Nardelli L, Mohan A, Herrmann SM. Reinforcing the role of magnesium in preventing cisplatin-induced nephrotoxicity: real-world evidence and clinical implications. Clin Kidney J. 2025;18(8):sfaf212. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40755966/)

\[7\] **Calvert Formula for Carboplatin Dosing** — Referenced in ASCO/NCCN guidelines for platinum-based chemotherapy in oncology.

------------------------------------------------------------------------

**Last Updated:** 2026-02-28 **Review Cycle:** Annually or upon new major evidence publication **Author Perspective:** Onco-nephrology clinical practice, board review emphasis


---

[Website version](https://urinenephrology.org/mastery/onconephrology/platinum-nephrotoxicity.html) · Markdown synchronized October 3, 2026.